Form 4: Dare Bioscience Executive John A. Fair Acquires 290,000 Stock Options
SEC Form 4 Filing
John A. Fair, Chief Commercial Officer of Dare Bioscience, acquired 290,000 stock options on March 12, 2024.
Summary
- On March 12, 2024, John A. Fair, the Chief Commercial Officer of Dare Bioscience, acquired 290,000 employee stock options.
- The exercise price of these options is $0.46.
- The options vest in 48 equal monthly installments starting one month after the grant date, contingent upon continuous service to the issuer.
- The options expire on March 12, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard insider transaction. The acquisition of stock options can be seen as a positive sign, but it's a routine part of executive compensation.
Positives
- The acquisition of stock options by a key executive could signal confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and alignment with shareholder interests.
Stakeholder Impact
- The acquisition of stock options by a key executive could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/12/2024 | Date of the stock option grant and transaction. |
| 03/12/2034 | Expiration date of the stock options. |
| 03/14/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.